Unicycive Therapeutics, Inc. (UNCY): EV/EBITDA Multiple

Public company logo of Unicycive (UNCY)

Market fluctuations in Unicycive Therapeutics (UNCY) share prices reflect an EV/EBITDA value of 0.00. Unicycive Therapeutics is developing a therapy system for renal pathologies, offering Oxylanum for phosphate control, which attracts dialysis patients awaiting an FDA verdict. The business relies on collaborations with specialized centers to test metabolic agents; however, threats remain regarding high development costs, a lack of sales, and the potential failure of clinical trials.

Unicycive - UNCY Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/15/2026)

UNCY (Unicycive): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Unicycive Therapeutics, Inc|UNCY - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Capitalization Unicycive|UNCY - Company Buyout Price
- issuer book value statistics:
Book Value per Share Unicycive Therapeutics|UNCY - Accounting Capitalization|Market Value to Book Value Ratio unicycive.com|UNCY - Total Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Unicycive Therapeutics|UNCY - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio unicycive.com|UNCY - Company Cumulative Debt|Debt to Book Value Unicycive Therapeutics|UNCY - Company Long-Term Debts|Company Short-Term Debt Unicycive Therapeutics|Quick Ratio unicycive.com
- financial results and valuation multiples details:
UNCY - Net Financial Result|Projected Future Earnings Unicycive Therapeutics|UNCY - Price to Earnings Ratio|Projected Price to Earnings Unicycive Therapeutics, Inc|UNCY - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Unicycive Therapeutics Inc.|UNCY - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Unicycive Therapeutics|UNCY - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months unicycive.com|UNCY - Earnings per share growth in current year|Earnings growth forecast for next year Unicycive Therapeutics
- sales and revenue indicators:
UNCY - Company Total Revenue|Company Future Sales Volume Unicycive Therapeutics|UNCY - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Unicycive Therapeutics, Inc|UNCY - Revenue Change YoY (Last 12 Months)
Initial company analysis:Unicycive Therapeutics, Inc (UNCY)
Product sample of Unicycive Therapeutics Inc.

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit, allowing investors to decouple market volatility from the actual value of assets. By analyzing fluctuations in the EV/EBITDA multiple, one can identify lucrative entry points into Unicycive Therapeutics (UNCY), where strict management discipline and fund support minimize risks as drugs are prepared for final approval.

Competitors of Unicycive Therapeutics

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Travere Corp TVTX|EV/EBITDA Multiple Ardelyx, Inc. ARDX|ProKidney Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Akebia Therapeutics, Inc. AKBA|TVRD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation DMAC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rockwell Medical, Inc.|Enterprise Value to Operating Income Before Depreciation CVKD (Cadrenal Therapeutics)|Enterprise Value to EBITDA Ratio CDT (Conduit Therapeutics)|CALT - Company Value to EBITDA|Renalytix - Enterprise Value to EBITDA Ratio|zyversa.com (ZVSA) - Company Value to EBITDA